ID: ALA5179783

Max Phase: Preclinical

Molecular Formula: C20H20N4O3

Molecular Weight: 364.41

Associated Items:

Representations

Canonical SMILES:  O=C(COc1ccc2cc(Oc3ccccn3)ccc2n1)N1CCNCC1

Standard InChI:  InChI=1S/C20H20N4O3/c25-20(24-11-9-21-10-12-24)14-26-19-7-4-15-13-16(5-6-17(15)23-19)27-18-3-1-2-8-22-18/h1-8,13,21H,9-12,14H2

Standard InChI Key:  XJXYHRAOHYWWBW-UHFFFAOYSA-N

Associated Targets(Human)

Sodium channel protein type VII alpha subunit 136 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HERG 29587 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 364.41Molecular Weight (Monoisotopic): 364.1535AlogP: 2.23#Rotatable Bonds: 5
Polar Surface Area: 76.58Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 7.82CX LogP: 2.03CX LogD: 1.47
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.75Np Likeness Score: -1.58

References

1. Patel MV, Peltier HM, Matulenko MA, Koenig JR, C Scanio MJ, Gum RJ, El-Kouhen OF, Fricano MM, Lundgaard GL, Neelands T, Zhang XF, Zhan C, Pai M, Ghoreishi-Haack N, Hudzik T, Gintant G, Martin R, McGaraughty S, Xu J, Bow D, Kalvass JC, Kym PR, DeGoey DA, Kort ME..  (2022)  Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain.,  63  [PMID:35436748] [10.1016/j.bmc.2022.116743]

Source